Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

R^1 is C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, substituted C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl-C_1-C_3 alkyl, substituted C_3-C_7 cycloalkyl-C_1-C_3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^2 is hydrogen, C_1-C_3 alkyl, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II



II;

R^3 is hydrogen or C_1-C_3 alkyl;

R^4 is hydrogen, halo, or C_1-C_3 alkyl;

R^5 is hydrogen or C_1-C_3 alkyl;

R^6 is hydrogen or C_1-C_6 alkyl; and

n is an integer from 1 to 6 inclusively.

2. (Original) The compound Claim 1 wherein R^5 is hydrogen and R^4 is hydrogen or halogen.

3. (Original) The compound of Claim 2 wherein R^4 is hydrogen.

4. (Original) The compound of any of Claims 1-3 wherein R^2 is hydrogen or C_1-C_3 alkyl.

5. (Previously Presented) The compound of Claim 1 wherein R^1 is phenyl, substituted phenyl, heterocycle, or substituted heterocycle.

6. (Currently Amended) The compound of Claim 1 wherein R^1 is phenyl, substituted phenyl, heterocycle or substituted heterocycle, wherein the heterocycle moiety is selected from the group consisting of furanyl, ~~thiophenyl~~thienyl, pyrrolyl, pyrrolidinyl, pyridinyl, N-methypyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, ozadiazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, N-acetylthiazolidinyl, pyrimidinyl, pyrazinyl, pyridazinyl, isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranyl, benzothiophenyl, and indolyl, and wherein substituted is taken to mean the ring moiety is substituted with one to three halo substituents; or substituted with one to two substituents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_1-C_4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C_1-C_2 alkoxy or with one to five halo groups each independently selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio, or pyrimidinyloxy moiety

can be further substituted with one to two substituents selected from the group consisting of halo, C_1-C_2 alkyl, and C_1-C_2 alkoxy; or substituted with one substituent selected from the group consisting of C_1-C_4 acyl and C_1-C_4 alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_1-C_4 alkylthio.

7. (Currently Amended) The compound of Claim 1 wherein R^1 is phenyl, substituted phenyl, heterocycle or substituted heterocycle, wherein the heterocycle moiety is selected from the group consisting of pyrindinyl, indolyl, benzofuranyl, furanyl, ~~thiophenyl~~thienyl, benzodioxolyl, and thiazolidinyl, and wherein substituted is taken to mean the ring moiety is substituted with one to three halo substituents; or substituted with one to two substituents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_1-C_4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C_1-C_2 alkoxy or with one to five halo groups each independently selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio; or pyrimidinyloxy moiety can be further substituted with one to two substituents selected from the group consisting of halo, C_1-C_2 alkyl, and C_1-C_2 alkoxy; or substituted with one substituent selected from the group consisting of C_1-C_4 acyl and C_1-C_4 alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_1-C_4 alkylthio.

8. (Cancelled)

9. (Withdrawn) A method for activating 5-HT_{1F} receptors in a mammal comprising administering to a mammal in need of such activation an effective amount of compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

R^1 is C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, substituted C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl-C_1-C_3 alkyl, substituted C_3-C_7 cycloalkyl-C_1-C_3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^2 is hydrogen, C_1-C_3 alkyl, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II



II;

R^3 is hydrogen or C_1-C_3 alkyl;

R^4 is hydrogen, halo, or C_1-C_3 alkyl;

R^5 is hydrogen or C_1-C_3 alkyl;

R^6 is hydrogen or C_1-C_6 alkyl; and

n is an integer from 1 to 6 inclusively.

10. (Withdrawn) The method according to Claim 9 wherein the mammal is a human.

11. (Withdrawn) A method for inhibiting neuronal protein extravasation in a mammal comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

R^1 is C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, substituted C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl-C_1-C_3 alkyl, substituted C_3-C_7 cycloalkyl-C_1-C_3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^2 is hydrogen, C_1-C_3 alkyl, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II



II;

R^3 is hydrogen or C_1-C_3 alkyl;

R^4 is hydrogen, halo, or C_1-C_3 alkyl;

R^5 is hydrogen or C_1-C_3 alkyl;

R^6 is hydrogen or C_1-C_6 alkyl; and

n is an integer from 1 to 6 inclusively.

12. (Withdrawn) The method according to Claim 11 wherein the mammal is a human.

13. (Withdrawn) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

R^1 is C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, substituted C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl-C_1-C_3 alkyl, substituted C_3-C_7 cycloalkyl-C_1-C_3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R^2 is hydrogen, C_1-C_3 alkyl, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II



II;

R^3 is hydrogen or C_1-C_3 alkyl;

R^4 is hydrogen, halo, or C_1-C_3 alkyl;

R^5 is hydrogen or C_1-C_3 alkyl;

R^6 is hydrogen or C_1-C_6 alkyl; and

n is an integer from 1 to 16 inclusively.

14. (Withdrawn) The method according to Claim 13 wherein the mammal is a human.

15-26. (Cancelled)

27. (Withdrawn) A process for preparing a 2-halo-6-(piperidin-4-carbonyl)pyridine compound of formula III



III;

where X is bromo or chloro;

R^8 is an amino protecting group, C_1-C_3 alkyl, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II



II;

R^6 is hydrogen or C_1-C_6 alkyl; and

n is an integer from 1 to 6 inclusively;

comprising

1) reacting a 2,6-dihalopyridine selected from 2,6-dibromopyridine and 2,6-dichloropyridine, with n-butyl lithium to form 2-halo-6-lithium-pyridine, and then
2) reacting the 2-halo-6-lithium-pyridine with a substituted aminocarbonylpiperidine compound of formula IV



IV;

wherein R^9 and R^{10} are each methyl, or R^9 and R^{10}, together with the nitrogen to which they are attached, combine to form azetidinyl, pyrrolidinyl, or piperidinyl.

28. (Withdrawn) The process of Claim 27 wherein X is bromo and the 2,6-dihalopyridine is 2,6-dibromopyridine.

29. (Withdrawn) The process of Claim 27 wherein R^9 and R^{10} are each methyl.

30. (Withdrawn) The process of Claim 27 wherein R^9 and R^{10}, together with the nitrogen to which they are attached, combine to form pyrrolidinyl.

31. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is methyl-*t*-butylether.

32. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is toluene.

33. (Withdrawn) A method for preparing a 2-bromo-6-(piperidin-4-carbonyl)pyridine compound of formula III



III;

wherein R^7 is C_1-C_3 n-alkyl, or an amino protecting group;

comprising reacting 2,6-dibromopyridine with n-butyl lithium to form 2-bromo-6-lithium-pyridine, and then reacting the 2-bromo-6-lithium-pyridine with a 4-(N,N'-dimethylamino)carbonyl piperidine compound of formula IV



IV;

in a methyl-*tert*-butyl ether solvent.

34. (Withdrawn) The process of Claim 28 wherein R^9 and R^{10} are each methyl.

35. (Withdrawn) The process of Claim 28 wherein R^9 and R^{10}, together with the nitrogen to which they are attached, combine to form pyrrolidinyl.

36. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is methyl-*t*-butylether.

37. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is methyl-*t*-butylether.

38. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is methyl-*t*-butylether.

39. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is methyl-*t*-butylether

40. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is methyl-*t*-butylether.

41. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is toluene.

42. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is toluene.

43. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is toluene.

44. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is toluene.

45. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is toluene.

46. (Previously Presented) The compound of Claim 5 wherein R^5 is hydrogen and R^4 is hydrogen or halogen.

47. (Previously Presented) The compound of Claim 46 wherein R^4 is hydrogen.

48. (Previously Presented) The compound of any one of Claims 5, 46, or 47 wherein R^2 is hydrogen or C_1-C_3 alkyl.

49. (Previously Presented) The compound of Claim 6 wherein R^5 is hydrogen and R^4 is hydrogen or halogen.

50. (Previously Presented) The compound of Claim 49 wherein R^4 is hydrogen.

51. (Previously Presented) The compound of any one of Claims 6, 49, or 50, wherein R^2 is hydrogen or C_1-C_3 alkyl.

52. (Previously Presented) The compound of Claim 7 wherein R^5 is hydrogen and R^4 is hydrogen or halogen.

53. (Previously Presented) The compound of Claim 52 wherein R^4 is hydrogen.

54. (Previously Presented) The compound of any of Claims 7, 52, or 53 wherein R^2 is hydrogen or C_1-C_3 alkyl.

55. (Previously Presented) A pharmaceutical formulation comprising a compound of any one of Claims 1-7, 46-54 and a pharmaceutical carrier, diluent, or excipient

56. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide or a pharmaceutically acceptable acid addition salt thereof.

57. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hemisuccinate salt.

58. (Previously Presented) The compound 2, 4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hydrochloride salt.